Table 3.
Breakthrough COVID-19 outcomes after tixagevimab/cilgavimab among patients with SARDs
| Outcome | SARD patients who received tixagevimab/cilgavimab (n=444) |
|---|---|
| Breakthrough COVID-19 | 83 (18.7%) |
| Incidence rate for breakthrough COVID-19 per 1000 person-months (95% CI) | 31.5 (24.7 – 38.2) |
| Severe COVID-19 | 7 (1.6%) |
| Hospitalizations | 7 (1.6%) |
| Deaths | 1 (0.2%) |
| Incidence rate for severe COVID-19 per 1000 person-months (95% CI) | 2.7 (0.7 – 4.6) |
| Median days from index date to infection (IQR) | 146 (98 – 209) |
| Outpatient COVID-19 treatmentsa | 63 (75.9%) |
| Nirmatrelvir/ritonavir | 43 (51.8%) |
| Outpatient monoclonal antibodies | 20 (24.1%) |
| No outpatient treatment | 15 (18.1%) |
| Inpatient COVID-19 treatmentsb | 5 (6.0%) |
SARD, systemic autoimmune rheumatic disease; CI, confidence interval; IQR, interquartile range
a
No patients received molnupiravir or outpatient remdesivir
b
Inpatient COVID-19 treatments included remdesivir, dexamethasone, baricitinib, and monoclonal antibodies. Two out of the seven patients with severe COVID-19 received outpatient monoclonal antibodies before being admitted for secondary complications of COVID-19.